Flexion Therapeutics Inc (NASDAQ:FLXN) has been assigned a $40.00 target price by equities research analysts at Cantor Fitzgerald in a research note issued on Thursday, May 4th. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 129.36% from the company’s previous close.
Several other equities research analysts have also recently commented on FLXN. BMO Capital Markets reaffirmed a “positive” rating and set a $33.00 price objective on shares of Flexion Therapeutics in a research report on Tuesday, February 7th. Wells Fargo & Co reissued an “outperform” rating and issued a $30.00 target price on shares of Flexion Therapeutics in a research report on Saturday, March 25th. Zacks Investment Research downgraded Flexion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 13th. Royal Bank of Canada reissued an “outperform” rating and set a $44.00 target price on shares of Flexion Therapeutics in a research note on Saturday, March 11th. Finally, Janney Montgomery Scott restated a “buy” rating and set a $30.00 price target on shares of Flexion Therapeutics in a report on Saturday, March 11th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $29.23.
Shares of Flexion Therapeutics (NASDAQ:FLXN) traded up 0.06% on Thursday, reaching $17.45. 295,147 shares of the company were exchanged. The company’s 50-day moving average price is $23.20 and its 200 day moving average price is $20.53. Flexion Therapeutics has a 12 month low of $9.60 and a 12 month high of $29.41. The company’s market cap is $554.16 million.
Flexion Therapeutics (NASDAQ:FLXN) last announced its earnings results on Thursday, May 4th. The specialty pharmaceutical company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by $0.02. On average, equities research analysts expect that Flexion Therapeutics will post ($3.72) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Cantor Fitzgerald Reiterates “$40.00” Price Target for Flexion Therapeutics Inc (FLXN)” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/05/19/cantor-fitzgerald-analysts-give-flexion-therapeutics-inc-flxn-a-40-00-price-target-updated.html.
In other Flexion Therapeutics news, insider Neil Bodick sold 5,000 shares of the stock in a transaction that occurred on Monday, April 17th. The stock was sold at an average price of $28.23, for a total transaction of $141,150.00. Following the completion of the transaction, the insider now owns 46,137 shares of the company’s stock, valued at $1,302,447.51. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Frederick W. Driscoll sold 3,000 shares of the firm’s stock in a transaction on Thursday, March 23rd. The stock was sold at an average price of $23.00, for a total value of $69,000.00. Following the transaction, the chief financial officer now owns 10,777 shares of the company’s stock, valued at $247,871. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,000 shares of company stock valued at $407,950. Corporate insiders own 18.00% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Peregrine Capital Management LLC acquired a new stake in shares of Flexion Therapeutics during the third quarter worth $14,126,000. State Street Corp raised its stake in shares of Flexion Therapeutics by 111.8% in the first quarter. State Street Corp now owns 829,254 shares of the specialty pharmaceutical company’s stock worth $22,316,000 after buying an additional 437,648 shares in the last quarter. Kingdon Capital Management L.L.C. raised its stake in shares of Flexion Therapeutics by 29.2% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 1,379,486 shares of the specialty pharmaceutical company’s stock worth $26,238,000 after buying an additional 311,865 shares in the last quarter. Novo A S raised its stake in shares of Flexion Therapeutics by 27.3% in the fourth quarter. Novo A S now owns 1,397,718 shares of the specialty pharmaceutical company’s stock worth $26,585,000 after buying an additional 300,000 shares in the last quarter. Finally, Pictet Asset Management Ltd. purchased a new stake in shares of Flexion Therapeutics during the first quarter valued at approximately $7,323,000. 62.25% of the stock is currently owned by institutional investors.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.